Company: ENTXW
Filing Date: 2025-06-05
Form Type: DEF 14A
Source: 0001178913-25-002111
Chunk: 58

Company: Entera Bio Ltd.
Filing Date: 2025-06-05
Form: DEF 14A
Chunk 58
---
 voted for any nominee who shall be designated by the present Board to fill the vacancy. It is not expected that any nominee will be unable or will decline to serve as a director. The section titled “Directors & Executive Officers” of this proxy contains more information about the leadership skills and other experience that caused the Nominating and Corporate Governance Committee and the Board to determine that Ms. Taitel should serve as the Class II director of the Company. We believe that Ms. Taitel possesses the experience, skills, and qualities to fully perform her duty as a director and contribute to our success. Ms. Taitel has been nominated because she possesses the highest standards of personal integrity, interpersonal and communication skills, is highly accomplished in her field, she understands the interests and issues that are important to our shareholders, and she is able to dedicate sufficient time to fulfilling their obligations as director. Our directors complement each other with their respective experiences, skills, and qualities. While our directors make up a diverse group in terms of age, gender and professional experience, together they comprise a cohesive body in terms of Board process and collaboration. Proposal Shareholders are being asked to adopt the following resolutions:

| (a) | “RESOLVED, that Ms. Haya Taitel is hereby elected to serve as a Class II member of the Board until the 2028 Annual Meeting.” |

Vote Required Election of the above-named director nominees requires the affirmative vote of a simple majority of our Ordinary Shares voted in person or by proxy, meaning that more votes must be cast “for” than “against” each director nominee in Proposal One. Each director nominee shall be voted separately. Abstentions and broker non-votes will have no effect on the outcome of Proposal One. Board Recommendation The Board recommends that our shareholders vote “FOR” the election of each of the directors nominated for service under this proposal. Entera Bio Ltd. | 2025 Annual Meeting Proxy Statement 35

| PROPOSAL TWO — RATIFICATION AND APPROVAL OF REVISED COMPENSATION TERMS AND ONE-TIME GRANT OF COMPENSATION TO MIRANDA TOLEDANO, OUR 
 CHIEF EXECUTIVE OFFICER AND A DIRECTOR                                                                                             |

Background On April 23, 2025 and April 28, 2025, the Compensation Committee and the Board, respectively, voted to approve revised compensation terms and one-time grant of compensation for Ms. Toledano in accordance with the terms below, which were deemed by the Board to be